Strong and Significant Associations of Single Nucleotide Variants (SNVs) in the Promoter and 3’-Untranslated Region (3’-UTR) of Vascular Endothelial Growth Factor (VEGF) Gene with Head and Neck Cancers - Ajaz, Sadia; Muneer, Rabbia; Siddiqa, Aisha; Memon, Muhammad Ali; Firasat, Sadaf; Abid, Aiysha; Khaliq, Shagufta (medRxiv, 2021)
Background Vascular Endothelial Growth Factor (VEGF) has a potent role in tumorigenesis and metastasis. However, data for the role of common single nucleotide variants (SNVs) in the highly polymorphic VEGF gene in head and neck cancers (HNCs) is limited in general and unavailable in South Asian populations.The present study addresses this shortfall. It investigates the association of two VEGF SNVs, −2578 C/A (rs699947) in the promoter region and +936 C/T (rs3025039) in 3’-UTR, with the risk of HNCs and tumour characteristics.Methods The study comprised 323 participants with 121 HNC patients and 202 controls. Germline DNA was isolated from peripheral blood samples. PCR-RFLP methods were optimized and validated by Sanger sequencing. After Hardy-Weinberg evaluation, the independent associations were analyzed by applying genetic models. The χ2 test of independence or Fisher’s Exact test (significant p-values at <0.05) were performed and ORs (odds ratios) with 95% confidence interval were tabulated.Results VEGF −2578 A-allele, A-carrier and AA genotypes had significant protective association against HNCs. The respective ORs were: 0.651 (0.469 – 0.904), 0.613 (0.381 – 0.985), and 0.393 (0.193 – 0.804). VEGF +936 T-allele, CT and T-carrier genotypes had significantly increased susceptibility for HNCs. The respective ORs were 1.882 (1.001 – 3.536), 2.060 (1.035 – 4.102), and 2.023 (1.032 – 3.966). Additionally, VEGF +936 CT and T-carrier genotypes showed significant associations with higher tumour grade (p-value <0.029, and <0.037, respectively).Conclusion The present study is the foremost report of independent and unique associations of the investigated VEGF SNVs with HNCs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol is approved by the ethical review committees of the participating institutions. These include the independent ethics review committee (IEC) of the International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi, Pakistan [ICCBS/IEC-016-BS/HT-2016/Protocol/1.0], the Ethics Review Committee (ERC) of the Atomic Energy Medical Centre (AEMC), Jinnah Postgraduate Medical Centre (JPMC), Karachi, Pakistan [Admin-3 (257)/2016], and the ERC, Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan. All the participants signed a written informed-consent form prior to sampling.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request.